(Q54540805)

31 May 2018

title

Experimental in vivo cross-resistance of vinca alkaloid drugs (English)

1 reference

20 April 2024

1 reference

20 April 2024

1 reference

20 April 2024

4

G Mathe

1 reference

31 May 2018

author name string

R. Maral

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7296754

20 April 2024

C. Bourut

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7296754

20 April 2024

E. Chenu

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7296754

20 April 2024

G. Mathe

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7296754

20 April 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=7296754

20 April 2024

publication date

1 January 1981

1 reference

31 May 2018

full work available at URL

http://link.springer.com/content/pdf/10.1007/BF00258480.pdf

file format

Portable Document Format

1 reference

http://link.springer.com/article/10.1007/BF00258480/fulltext.html

20 April 2024

1 reference

http://link.springer.com/content/pdf/10.1007/BF00258480

20 April 2024

1 reference

Cancer Chemotherapy and Pharmacology

20 April 2024

published in

1 reference

31 May 2018

volume

5

1 reference

31 May 2018

page(s)

197-199

1 reference

31 May 2018

issue

3

1 reference

31 May 2018

https://scigraph.springernature.com/pub.10.1007/bf00258480

exact match

0 references

cites work

Phase-II trial with vindesine for regression induction in patients with leukemias and hematosarcomas

1 reference

12 December 2020

Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukemia

1 reference

12 December 2020

Vindesine a short review of preclinical and first clinical data

1 reference

12 December 2020

Phase I anti-cancer agents: vindesine (desacetyl vinblastine amide sulfate).

1 reference

12 December 2020

Decreased retention of actinomycin D as the basis for cross-resistance in anthracycline-resistant sublines of P388 leukemia

1 reference

12 December 2020

Phase II clinical trial with vindesine for remission induction in acute leukemia, blastic crisis of chronic myeloid leukemia, lymphosarcoma, and hodgkin's disease: absence of cross-resistance with vincristine

1 reference

12 December 2020

In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukemia.

1 reference

12 December 2020

A new class of antitumor compounds: 5'-nor and 5',6'-seco derivatives of vinblastine-type alkaloids

1 reference

12 December 2020

A study of the cross-resistance of vincristine and vindesine in reinduction therapy for acute lymphocytic leukemia in relapse. A report for Children's Cancer Study Group.

1 reference

12 December 2020

Comparative effects of vincristine and vindesine on cell cycle kinetics in vitro

1 reference

12 December 2020

Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Deacetyl vinblastine amide (vindesine) sulfate

1 reference

12 December 2020

Cross resistance between actinomycin-D, adriamycin and vincristine in a murine solid tumour in vivo.

1 reference

12 December 2020

Cancer Treatment Reports

15

62

805

G Mathé

1978

1 reference

Treatment of rhabdomyosarcoma in children with surgery, radiotherapy and chemotherapy

20 April 2024

17

1 reference

20 April 2024

Identifiers

DOI

10.1007/BF00258480

1 reference

31 May 2018

1 reference

31 May 2018